OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR LOW-DOSE CYTARABINE (LDAC) IN THE AZA-AML-001 STUDY

被引：0
|
作者：
Seymour, J. F. [1 ]
Doehner, H. [2 ]
Kumar, R. [3 ]
Stone, R. M. [4 ]
Wierzbowska, A. [5 ]
Bernal del Castillo, T. [6 ]
Falantes, J. [7 ]
Delaunay, J. [8 ]
Sabloff, M. [9 ,10 ]
Voso, M. T. [11 ]
Kim, I. [12 ]
Ram, R. [13 ]
Gau, J. P. [14 ]
Songer, S. [15 ]
Lucy, L. M. [15 ]
Beach, C. [15 ]
Dombret, H. [16 ]
机构：
[1] Peter MacCallum Canc Ctr, East Melbourne, Australia
[2] Univ Ulm Klinikum, Ulm, Germany
[3] Canc Care Manitoba, Winnipeg, MB, Canada
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Med Univ Lodz, Lodz, Poland
[6] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain
[7] Hosp Univ Virgen del Rocio, Inst BioMed Sevilla, Seville, Spain
[8] CHU Nantes, Hotel Dieu, F-44035 Nantes 01, France
[9] Univ Ottawa, Ottawa, ON, Canada
[10] Ottawa Hosp, Res Inst, Ottawa, ON, Canada
[11] Univ Roma Tor Vergata, Rome, Italy
[12] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[13] Rabin Med Ctr, Petah Tiqwa, Israel
[14] Taipei Vet Gen Hosp, Taipei, Taiwan
[15] Celgene Corp, Summit, NJ USA
[16] Univ Paris Diderot, Inst Univ Hematol, Hop St Louis, Paris, France
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E954
引用
收藏
页码：381 / 381
页数：1
相关论文
共 50 条
  • [31] Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML)
    Kadia, Tapan
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Daver, Naval
    Jabbour, Elias
    Pemmaraju, Naveen
    Verstovsek, Srdan
    Burger, Jan A.
    Wierda, William G.
    Konopleva, Marina
    DiNardo, Courtney D.
    Jain, Nitin
    Brandt, Mark
    Tuttle, Carla
    Wang, Xuemei
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    BLOOD, 2014, 124 (21)
  • [32] Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).
    Dinardo, Courtney Denton
    Stein, Anthony Selwyn
    Stein, Eytan M.
    Fathi, Amir Tahmasb
    Schuh, Andre C.
    Fernandez, Pau Montesinos
    Odenike, Olatoyosi
    Kantarjian, Hagop M.
    Stone, Richard M.
    Collins, Robert
    Martinelli, Giovanni
    Arnan, Montserrat
    Wu, Bin
    Koralek, Daniel O.
    Van Oostendorp, Jason
    Gong, Jing
    MacBeth, Kyle J.
    Vyas, Paresh
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Results of omacetaxine plus low-dose cytarabine (LD-araC) in older patients with acute myeloid leukemia (AML).
    Kadia, Tapan M.
    Daver, Naval Guastad
    Ravandi, Farhad
    Jabbour, Elias
    Pemmaraju, Naveen
    Pierce, Sherry
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Low-Dose Azacitidine (AZA) for Treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapse after Allogeneic Hematopoietic Cell Transplant (HCT)
    Ueda, Masumi
    Lazarus, Hillard M.
    Cooper, Brenda
    Caimi, Paolo
    Creger, Richard
    Little, Jane A.
    Baer, Linda
    Brister, Lauren
    Malek, Ehsan
    Metheny, Leland, III
    Tomlinson, Benjamin
    Gerson, Stan L.
    Oran, Betul
    de Lima, Marcos
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S212 - S213
  • [35] Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial
    Ravandi, Farhad
    Wei, Andrew H.
    Doehner, Hartmut
    Sayar, Hamid
    Montesinos, Pau
    Dombret, Herve
    Selleslag, Dominik
    Porkka, Kimmo
    Jang, Jun Ho
    Skikne, Barry
    Beach, C. L.
    Tian, Yu
    Roboz, Gail J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S252 - S253
  • [36] Survival Outcomes for Patients (pts) in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine (Oral-AZA) or Placebo (PBO)
    Pfeilstoecker, M.
    Ravandi, F.
    Montesinos, P.
    Papayannidis, C.
    Dombret, H.
    Lai, Y.
    Petrlik, E.
    Prebet, T.
    Doehner, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 48 - 49
  • [37] Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia
    Zeidan, Amer M.
    Schuster, Michael W.
    Krauter, Jurgen
    Maertens, Johan A.
    Gyan, Emmanuel
    Joris, Magalie
    Menne, Tobias F.
    Vyas, Paresh
    Ma, Weidong Wendy
    O'Connell, Ashleigh
    Zeremski, Mirjana
    Kudla, Arthur
    Chan, Geoffrey
    Sekeres, Mikkael A.
    BLOOD, 2019, 134
  • [38] Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.
    Heuser, Michael
    Robak, Tadeusz
    Montesinos, Pau
    Leber, Brian
    Fiedler, Walter M.
    Pollyea, Daniel Aaron
    Brown, Andrew
    O'Connell, Ashleigh
    Ma, Wendy
    Chan, Geoffrey
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).
    Roboz, Gail J.
    Wei, Andrew H.
    Ravandi, Farhad
    Pocock, Christopher
    Montesinos, Pau
    Dombret, Herve
    Porkka, Kimmo
    La Torre, Ignazia
    Skikne, Barry
    Zhong, Jianhua
    Beach, C. L.
    Dohner, Hartmut
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial
    Wei, Andrew H.
    Döehner, Hartmut
    Sayar, Hamid
    Ravandi, Farhad
    Montesinos, Pau
    Dombret, Hervé
    Selleslag, Dominik
    Porkka, Kimmo
    Jang, Jun Ho
    Skikne, Barry
    Beach, C. L.
    Tian, Yu
    Roboz, Gail J.
    BLOOD, 2021, 138
12345